In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturing

Environmental goals move up the agenda for pharma and its partners. Digital tools grow in importance and the COVID-19 pandemic continues to disrupt supply chains and regulatory procedures.

US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

Voluntary Limits On Antibacterial Discharges Increase As Fear Of Resistance Grows

Pharmaceutical companies are ratcheting up voluntary efforts to control discharges of antimicrobials from their plants and those of their active pharmaceutical ingredient suppliers so they won’t contribute to antimicrobial resistance. But will it be enough to fend off regulation in countries like India?

Data-Sharing Key To US Supply Chain Resilience And Keeping Drug Costs Under Control

Aside from a few high-profile exceptions, the biopharma industry supply chain has remained secure and resilient during the COVID-19 pandemic, outperforming retail and consumer goods. Chip Davis, Jr., head of the Healthcare Distribution Alliance, spoke with In Vivo about the need for a long-term industrial policy for drug manufacturing, real-time data-sharing and transparency in the supply chain, and minimizing disruptions.

How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus

FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.

Chapter sponsored by:

How Science Helps Manufacturing Evolve To Meet The Complex Challenges Of Drug Development 

manufacturing

In 2022, the worlds of technology and science will continue to merge at an unprecedented rate, allowing for the faster development and delivery of novel patient-centric treatments, such as cell and gene therapies. But novelty is naturally accompanied by risk.

Download Now

About Rentschler Biopharma

At Rentschler Biopharma, we enable to your product's success by translating medical research into outstanding biopharmaceuticals for the treatment of patients with serious and rare diseases.

Learn More »

Outlook 2022 e-Book

Outlook 2022 cover

Download a PDF copy of the Outlook 2022 collection, including Scrip 100 league tables.

ACCESS NOW
UsernamePublicRestriction

Register